Alumis cuts IPO size, but nets $250M for immune drug work
2024-06-28
Still, the IPO announced Thursday comes in below projections Alumis set earlier this week. The company had expected to sell about 17.7 million shares at $16 to $18 apiece, guaranteeing it at least $282.5 million. Instead, Alumis sold about 13.1 million shares at the low end of that range, and boosted its haul with a $40 million private stock sale to AyurMaya Capital Management, one of its top equity holders.
Shares will begin trading Friday on the Nasdaq stock exchange.
Even though the offering is smaller than Alumis intended, it’s still the third-largest for a biotech this year, according to BioPharma Dive data. It also ranks among the most lucrative offerings since the final months of 2021, when the demand for sector IPOs cooled following a multi-year bull run.
The company is capitalizing on interest in developers of drugs for autoimmune diseases, which have seen an uptick in venture funding, acquisitions and new stock offerings. Since the start of 2023, IPOs from Acelyrin, Kyverna Therapeutics, AbiVax, Apogee Therapeutics and now Alumis have all surpassed $200 million in proceeds, a mark only matched by four other companies.
Alumis’s lead program is what’s known as a TYK2 inhibitorTYK2 inhibitor, a type of oral drug that’s shown promise treating multiple immunological conditions. One TYK2 drug, Bristol Myers Squibb’s Sotyktu, was approved by the Food and Drug Administration in 2022 as a treatment for plaque psoriasis.
Alumis claims its drug, called ESK-001, could be more potent and selective than Sotyktu, though that hasn’t yet been proven in testing. It also faces several other competitors. Takeda has a drug in late-stage testing that it acquired from Nimbus Therapeutics. Privately held biotechs Sudo Biosciences and Priovant Therapeutics, among others, are also working on next-generation TYK2 inhibitorsTYK2 inhibitors.
Previously known as Esker Therapeutics, Alumis was founded in 2021 and incubated by San Francisco-based Foresite Labs. With a 33% stake, Foresite Capital, the investment firm that formed Foresite Labs, is the company’s largest shareholder.
The company is led by Martin Babler, a former Genentech executive who previously ran Principia Biopharma, which Sanofi acquired in 2020.
After a fast start to 2024, the pace of new biotech stock issues has slowed. Only four biotechs priced offerings during the second quarter, compared to eight in the first three months of the year, according to BioPharma Dive data. Performance has lagged as well, with most of this year’s class trading below their offering price.
'
更多内容，请访问原始网站
文中所述内容并不反映新药情报库及其所属公司任何意见及观点，如有版权侵扰或错误之处，请及时联系我们，我们会在24小时内配合处理。
来和芽仔聊天吧
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。